Policy Watch: 20 Regulatory Updates — June 21, 2026
Policy WatchJune 21, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 20 Regulatory Updates — June 19, 2026
Policy WatchJune 19, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
Appeal Court Upholds Stay in THC-Impaired Driving Charge in Saskatoon
THC impaired driving legal challenges remain complex due to forensic limitations in measuring impairment. The Saskatchewan appeal court upheld a stay of charges in a fatal THC-impaired driving case. This highlights ongoing difficulties in using THC blood…
Georgia Lawmakers Pass Bill To Expand Medical Marijuana Access, Sending It To Governor’s Desk
The Georgia medical cannabis expansion bill recently passed by lawmakers aims to improve patient access to regulated cannabis products. This legislation could enhance clinical oversight and broaden qualifying conditions. Patients and clinicians should…